Similarly, patients in high PCA score group showed remarkable survival benefit (log‐rank test, p = 0.046; Figure 3A) as a result of more active response to anti‐PD‐L1 therapy (Figure 3B‐C), which showed a high uniformity with a classical marker, the tumor mutation burden (TMB, Figure 3D). The gene discussed is CD274; the disease is neoplasm.